PRAX

Praxis Precision Medicines Inc

PRAX, USA

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance. The company's platforms include cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and solidus to discover and develop antisense oligonucleotide. It also develops Ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase 3 clinical trial for the treatment of essential tremor; Vormatrigine, a small molecule targeting the hyperexcitable state of sodium-channels in the brain to treat focal onset epilepsy; Relutrigine for the treatment of developmental and epileptic encephalopathies; PRAX-020 to treat KCNT1; and PRAX-050. In addition, the company develops Elsunersen, a clinical-stage ASO designed to regulate NaV1.2 expression for the treatment of SCN2A-DEE; PRAX-080 that targets PCDH19-related developmental epilepsy; PRAX-090 for targeting SYNGAP1 loss-of-function; and PRAX-100 that targets SCN2A LoF mutations. It has a license agreement with RogCon Inc.; and research collaboration and license agreement with Ionis Pharmaceuticals, Inc. Praxis Precision Medicines, Inc. was incorporated in 2015 and is based in Boston, Massachusetts.

https://praxismedicines.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
PRAX
stock
PRAX

Praxis Precision Medicines (PRAX): Revisiting Valuation After Major FDA Progress and Positive CNS Trial Updates simplywall.st

Read more →
PRAX
stock
PRAX

Praxis Precision Medicines Plans New Drug Application TipRanks

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$323.9333

Analyst Picks

Strong Buy

8

Buy

3

Hold

0

Sell

0

Strong Sell

1

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

17.03

Low 1

High 3

Return on Equity (ROE)

-

Very Low

-21.52 %

Low 5%

High 25%

Return on Assets (ROA)

-

Very Low

-18.65 %

Low 2%

High 10%

Debt to Equity

-

Very High

0.15

Low 1

High 0.3

Investors

* Institutions hold a combined 120.99% of the total shares of Praxis Precision Medicines Inc

1.

HHG PLC

(12.0354%)

since

2025/06/30

2.

Adage Capital Partners Gp LLC

(9.3806%)

since

2025/06/30

3.

Cormorant Asset Management, LLC

(7.7199%)

since

2025/06/30

4.

BlackRock Inc

(7.5542%)

since

2025/06/30

5.

T. Rowe Price Associates, Inc.

(6.9981%)

since

2025/06/30

6.

Morgan Stanley - Brokerage Accounts

(5.826%)

since

2025/06/30

7.

Vanguard Group Inc

(5.7751%)

since

2025/06/30

8.

Soleus Capital Management, L.P.

(4.5927%)

since

2025/06/30

9.

Point72 Asset Management, L.P.

(4.5325%)

since

2025/06/30

10.

Perceptive Advisors LLC

(3.5769%)

since

2025/06/30

11.

State Street Corp

(3.3164%)

since

2025/06/30

12.

Baker Bros Advisors LP

(3.2755%)

since

2025/06/30

13.

Deerfield Management Co

(3.2634%)

since

2025/06/30

14.

Vanguard Total Stock Mkt Idx Inv

(3.199%)

since

2025/07/31

15.

Assenagon Asset Management SA

(2.8708%)

since

2025/06/30

16.

Driehaus Capital Management LLC

(2.5226%)

since

2025/06/30

17.

Bank of America Corp

(2.154%)

since

2025/06/30

18.

Geode Capital Management, LLC

(2.146%)

since

2025/06/30

19.

iShares Russell 2000 ETF

(2.0438%)

since

2025/08/31

20.

Janus Henderson Global Life Sciences D

(1.9119%)

since

2025/06/30

21.

Janus Henderson Global Life Sciences

(1.9119%)

since

2025/06/30

22.

US Small-Cap Growth II Equity Comp

(1.8692%)

since

2025/06/30

23.

CIBC Global Asset Management Inc

(1.8469%)

since

2025/06/30

24.

Renaissance Global Health Care

(1.845%)

since

2025/05/31

25.

Balyasny Asset Management LLC

(1.7542%)

since

2025/06/30

26.

Janus Global Life Science AUSD

(1.5925%)

since

2025/06/30

27.

Janus Henderson Glb Life Scn I2 USD

(1.557%)

since

2025/07/31

28.

Franklin Resources Inc

(1.4924%)

since

2025/06/30

29.

SPDR® S&P Biotech ETF

(1.4358%)

since

2025/08/31

30.

T. Rowe Price Health Sciences

(1.4211%)

since

2025/07/31

31.

T. Rowe Price New Horizons

(1.2509%)

since

2025/07/31

32.

T. Rowe Price Integrated US Sm Gr Eq

(1.2278%)

since

2025/07/31

33.

T. Rowe Price Integrated US SmCapGrEq

(1.2278%)

since

2025/06/30

34.

Janus Henderson Hrzn Biotec E2 USD

(1.0077%)

since

2025/06/30

35.

Vanguard Institutional Extnd Mkt Idx Tr

(0.9757%)

since

2025/07/31

36.

Franklin Biotechnology Discv A(acc)USD

(0.952%)

since

2025/08/31

37.

Fidelity Small Cap Index

(0.8496%)

since

2025/06/30

38.

Invesco MSCI World ETF

(0.8182%)

since

2025/07/31

39.

iShares Russell 2000 Value ETF

(0.6844%)

since

2025/08/31

40.

T. Rowe Price New Horizons Tr-A

(0.5737%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-3.37

Latest Release

Date

2025-09-30

EPS Actual

-3.36

EPS Estimate

-3.47

EPS Difference

0.11

Surprise Percent

3.17%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(3)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(2.5)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(2.5)
Value
Overpriced(3)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.